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Abstract
Maintenance therapy after autologous stem cell transplantation (ASCT) is recommended for use in multiple myeloma (MM);
however, more data are needed on its impact on health-related quality of life (HRQoL). Presented here is an analysis of HRQoL in
a Connect MM registry cohort of patients who received ASCT ± maintenance therapy. The Connect MM Registry is one of the
earliest and largest, active, observational, prospective US registry of patients with symptomatic newly diagnosed MM. Patients
completed the Functional Assessment of Cancer Therapy-MM (FACT-MM) version 4, EuroQol-5D (EQ-5D) questionnaire, and
Brief Pain Inventory (BPI) at study entry and quarterly thereafter until death or study discontinuation. Patients in three groups
were analyzed: any maintenance therapy (n = 244), lenalidomide-only maintenance therapy (n = 169), and no maintenance
therapy (n = 137); any maintenance and lenalidomide-only maintenance groups were not mutually exclusive. There were no
significant differences in change from pre-ASCT baseline between any maintenance (P = 0.60) and lenalidomide-only mainte-
nance (P = 0.72) versus no maintenance for the FACT-MM total score. There were also no significant differences in change from
pre-ASCT baseline between any maintenance and lenalidomide-only maintenance versus no maintenance for EQ-5D overall
index, BPI, FACT-MM Trial Outcomes Index, and myeloma subscale scores. In all three groups, FACT-MM, EQ-5D Index, and
BPI scores improved after ASCT; FACT-MM and BPI scores deteriorated at disease progression. These data suggest that post-
ASCT any maintenance or lenalidomide-only maintenance does not negatively impact patients’ HRQoL. Additional research is
needed to verify these findings.
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Introduction
Multiple myeloma (MM) is a hematologic malignancy of plas-
ma cells that has an age-adjusted incidence of 6.5 per 100,000
persons per year in the USA [1]. In 2017, an estimated 30,280
living in the USAwill be diagnosed with MM, and 12,590 will
die of the disease [2]. Although the rates of newMM diagnoses
have been increasing at an average of 0.8% per year during the
past decade, advances in the development of anti-myeloma
therapies have expanded treatment options and resulted in a
parallel decrease of death rates by an average of 0.8% per year
[1]. However, despite the introduction of novel therapies, MM
continues to be incurable and patients ultimately relapse.
Autologous stem cell transplantation (ASCT) is a standard
of care for eligible patients with newly diagnosed MM
(NDMM) [3–5]. Despite improvements in treatment, ASCT is
not curative for most patients, with more than half of patients
relapsing within 2 to 3 years after ASCT if they did not receive
post-ASCT treatment [6–10]. Thus, a key treatment goal for
transplant-eligible patients with NDMM is to extend post-
ASCT remission. Results of analyses examining survival out-
comes and tolerability associated with interferon, corticoste-
roid, and thalidomide maintenance therapy have been inconsis-
tent [11–13]. Bortezomib maintenance has also been tested,
with increased progression-free survival (PFS) noted [14, 15].
Findings from several randomized controlled trials with
continuous lenalidomide therapy have shown significant im-
provements in PFS [5, 8, 10, 16] and overall survival (OS) [8],
with moderate and manageable adverse event (AE) profiles. A
recent meta-analysis of lenalidomide maintenance therapy
post-ASCT data from three of these studies [5, 8, 10], which
were not individually powered to assess OS, reported an OS
benefit associated with lenalidomide maintenance therapy
compared with control (no maintenance therapy) [17].
Lenalidomide maintenance therapy has been approved by
the FDA and EMA and is recommended for use after ASCT
in several guidelines for MM treatment. However, important
questions remain, including the optimal length ofmaintenance
treatment, patient subsets that will benefit most/least from
maintenance, and the role of combination therapies for main-
tenance. Components of maintenance tend to emphasize sur-
vival benefit and manageable toxicities; opponents argue that
the risks of long-term toxic effects outweigh the clinical ben-
efits and advocate for the inclusion of a treatment-free interval
to preserve patients’ health-related quality of life (HRQoL)
[18]. Because the prolonged treatment duration of mainte-
nance therapies requires tolerability and minimal impact on
HRQoL, excessive toxicity from otherwise promising agents
has previously limited the applicability of these agents in this
setting [18, 19].
Patient-reported outcomes (PROs) contribute an additional
valuable perspective in the ongoing maintenance discussion
by quantifying the effects of long-term therapy on HRQoL
directly from patients. Few HRQoL analyses of patients un-
dergoing post-ASCT maintenance therapy have been pub-
lished [20, 21], and none report real-world outcomes in com-
munity settings. The Connect MM Registry enrolled more
than 3000 patients with NDMM, the vast majority (> 80%)
from community settings. This registry was established as a
research initiative to better understand the natural history and
management of MM across community, academic, and gov-
ernment treatment centers. In addition to describing practice
patterns, a secondary objective for the registry is to character-
ize the HRQoL of patients and to explore its association with
treatment regimens/sequence and clinical outcomes. Data
from the Connect MM registry have been used previously to
establish baseline demographic and disease characteristics and
to analyze the incidence of second primary malignancies
among patients treated with lenalidomide [22, 23]. Presented
here is an analysis of PROs fromCohort 1 of the Connect MM
registry (n = 1493), which includes patients with NDMMwho
received ASCT and did or did not receive maintenance thera-
py during the follow-up period, to provide insights on the
effects of maintenance therapy on HRQoL based on patients’
experiences.
Patients and methods
Study design and study population
Connect MM registry design, which has been described pre-
viously in detail (clinicaltrials.gov identifier: NCT01081028),
collects longitudinal data on patients with NDMM in the
USA. In order to minimize bias and better understand the
representativeness of the Registry population, consecutive
MM patients presenting to the sites were evaluated for
potential enrollment, though participation in the registry was
voluntary. All medical treatment (including medications,
follow-up, and post-treatment laboratory testing) was admin-
istered at the treating physician’s discretion as per standard of
care. Patients aged ≥18 years who had symptomatic NDMM
within 2 months before study entry and signed informed con-
sent were eligible for inclusion in the registry. MM diagnosis
was asked to be defined per International Myeloma Working
Group criteria [24]. The registry is sponsored by Celgene
Corporation.
The registry comprises two cohorts: Cohort 1 (n = 1493)
includes patients enrolled from September 2009 to December
2011, and Cohort 2 (n = 1518) includes patients enrolled from
December 2012 to April 2016. Using available site screening
information, 92% of all screened patients were enrolled.
Patients were followed for treatment and outcomes for as
many as 8 years or until discontinuation from the study. The
analysis population for the present study comprised Cohort 1
patients who completed induction therapy and first-line ASCT
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and had or had not received maintenance therapy post-ASCT
(Fig. 1). To reduce potential sources of bias, patients who
received allogeneic, tandem, or unknown types of transplant
were excluded. Also, patients who received consolidation (de-
fined as treatment received for < 60 days following transplant)
before maintenance therapy were excluded from this analysis.
The analysis population was categorized into three groups: (1)
any type of maintenance therapy, including lenalidomide-
only; (2) lenalidomide-only maintenance therapy; or (3) no
maintenance therapy.
Data collection and measures
In the Connect MM registry, PRO measures were adminis-
tered to assess overall HRQoL (Functional Assessment of
Cancer Therapy–General; FACT-G), myeloma-specific con-
cerns (FACT-Multiple Myeloma subscale; FACT-MM), pain
severity (Brief Pain Inventory; BPI), and health utilities
(EuroQol Research Foundation EQ-5D questionnaire)
[25–28]. PROs were completed in the clinic at study enroll-
ment (study baseline) and approximately quarterly (based on
frequency of clinic visits) thereafter until the end of the study’s
follow-up period, early study discontinuation, or death. In
efforts to minimize the variability of HRQoL scores among
patients who are treated at their physicians’ discretion (prov-
ing more difficult to collect HRQoL assessments closer to the
initiation of maintenance therapy), HRQoL assessments ana-
lyzed were those collected at study baseline, after induction
therapy but prior to ASCT (analytical baseline or t0), and
quarterly from 100 days post-ASCT until the end of mainte-
nance therapy or until progressive disease, discontinuation, or
death (analytic period).
The FACT-MM questionnaire consists of the four core
FACT HRQoL subscales measuring physical, functional, so-
cial, and emotional well-being (FACT-G; 27 items) and an
additional subscale (MM subscale) measuring MM-specific
concerns (14 items). Following standard FACT instructions,
items were rated using a 0- to 4-point scale based on the past
7 days, with higher scores indicating better HRQoL and fewer
MM-related symptoms. Three scores were calculated for anal-
ysis: the FACT-MM total score (all domains; scale, 0–164),
the trial outcome index (TOI; physical, functional, and MM-
specific domains; scale, 0–112), and an MM subscale score
(scale, 0–56). The EQ-5D is a general, nondisease measure of
health utilities and assesses five dimensions: mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression.
Summary assessments for EQ-5D use the visual analog scale
and an index score (scale, − 0.109 to 1), with higher scores
indicating better health states. The BPI short form assesses the
existence and intensity of pain on a scale of 0 to 10 (none to
worst) and categorizes pain asmild (1–4), moderate (5–6), and
severe (7–10).
The completion rates for each HRQoL instrument and time
point were calculated as the number of patients who complet-
ed the instrument divided by the number of patients who had
not discontinued or died by that time point. The analysis was
conducted using a mixed model which is robust under missing
at random (MAR) assumptions.
Statistical analysis
SAS Proc Mixed with a random effects unstructured covari-
ance matrix to estimate mixed regression models was used to
test the null hypothesis of no HRQoL difference between pa-
tients receiving any maintenance versus no maintenance ther-
apy, and patients receiving lenalidomide-only maintenance
versus no maintenance therapy. A quadratic growth model
was applied with time as a continuous variable (given that
ASCT can occur at any fractional quarterly period post-
enrollment and having started at 100 days post-ASCT) adjust-
ed for potential confounders including: study baseline renal
impairment and presence of del(17p); analytic baseline history
HRQoL Assessment Tools
 • EQ-5D; primary endpoint of analysis
 • FACT-MM
 • Brief Pain Inventory
No Maintenance
Any Maintenancea
Analysis Period
Treatment at physician’s discretion
Quarterly
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a 69% of these patients received LEN-Only Maintenance
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Fig. 1 Connect MM HRQoL
analysis design. Autologous stem
cell transplant (ASCT), EuroQol
Research Foundation EQ-5D
questionnaire (EQ-5D),
Functional Assessment of Cancer
Therapy-Multiple Myeloma
(FACT-MM); health-related
quality of life (HRQoL),
lenalidomide (LEN), progressive
disease (PD)
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of monoclonal gammopathy of undetermined significance and
peripheral neuropathy; day-100 post-ASCT albumin; and
first-regimen first-course treatment of novel therapy (immu-
nomodulatory agent or protease inhibitor), triplet therapy, and
lenalidomide. The complete list of variables included in the
analysis is listed in Table 5 (Online Resource 1). A post-hoc
power assessment was conducted to determine whether the
study was powered to find differences in PROs. For any
Table 1 Patient characteristics
Characteristic Anymaintenance
therapy (n = 244)
Lenalidomide-only
maintenance therapy (n = 169)
No maintenance
therapy (n = 137)
Age (years)
Median (range) 60 (24–78) 60 (24–74) 60 (27–75)
< 65 166 (68.0) 120 (71.0) 96 (70.1)
65 to <75 75 (30.7) 49 (29.0) 40 (29.2)
Men 154 (63.1) 106 (62.7) 77 (56.2)
Race
White 209 (85.7) 144 (85.2) 114 (83.2)
Black 28 (11.5) 20 (11.8) 16 (11.7)
ECOG PS
0–1 149 (61.0) 111 (65.7) 95 (69.3)
2–3 20 (8.2) 9 (5.4) 7 (5.1)
Not specified 75 (30.7) 49 (29.0) 35 (25.5)
ISS stagea
I 72 (29.5) 53 (31.4) 42 (30.7)
II 68 (27.9) 50 (29.6) 31 (22.6)
III 54 (22.1) 32 (18.9) 35 (25.5)
Not specified 50 (20.5) 34 (20.1) 29 (21.2)
Type of induction therapy
Lenalidomide-containing 143 (58.6) 108 (63.9) 72 (52.6)
Bortezomib-containing 209 (85.7) 141 (83.4) 108 (78.8)
Alkylator-containing 44 (18.0) 27 (16.0) 15 (10.9)
Novel agents 243 (99.6) 168 (99.4) 133 (97.1)
Triplet 153 (62.7) 110 (65.1) 69 (50.4)
IMWG risk
Low 28 (11.5) 25 (14.8) 16 (11.7)
Standard 93 (38.1) 64 (37.9) 57 (41.6)
High 50 (20.5) 33 (19.5) 20 (14.6)
Missing/not specified 73 (29.9) 47 (27.8) 44 (32.1)
Creatinine category
> 2.0 mg/dL 27 (11.1) 17 (10.1) 23 (16.8)
≤ 2.0 mg/dL 217 (88.9) 152 (89.9) 114 (83.2)
Albuminb
< 3.5 g/dL 26 (10.7) 16 (9.5) 24 (17.5)
≥ 3.5 g/dL 173 (70.9) 123 (72.8) 89 (65.0)
Abnormal platelet count
(≤ 150 × 109/L)
63 (25.8) 40 (23.7) 40 (29.2)
Neutropenia (ANC ≤ 1.5 × 109/L) 21 (8.6) 11 (6.5) 13 (9.5)
Anemia (Hb < 10 g/dL) 23 (9.4) 12 (7.1) 12 (8.8)
Abbreviations:ANC absolute neutrophil count,ASCTautologous stem cell transplant,ECOGEastern Cooperative
Oncology Group, Hb hemoglobin, IMWG International Myeloma Working Group, ISS International Staging
System, PS performance status
Values shown are n (%) unless otherwise indicated
a As defined in: Greipp PR, et al. [31]
b Data provided for albumin are for 100 days post-ASCT
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maintenance (n = 244) or lenalidomide-only maintenance
(n = 169) vs no maintenance (n = 137): 99% power to detect
minimal clinically important differences in HRQoL scales
with two-sided P value of 0.05.
Data availability The datasets generated during and/or ana-
lyzed during the current study are available from the corre-
sponding author on reasonable request.
Results
Patient characteristics
Between September 2009 and December 2011, 1493 patients
had enrolled in Cohort 1 of the Connect MM registry from
community (81%), academic (18%), or government (1%)
centers. The mean time from initial diagnosis to enrollment
in this registry was 25 days. Of the 1493 patients enrolled, 548
patients received ASCT; of these, 244 met the analysis criteria
for any maintenance, 169 for lenalidomide-only maintenance,
and 137 for no maintenance (Table 1; Fig. 2). At study entry,
the median age was 60 years (range, 24–78 years), 61% were
men, and 85% were white. Most patients had an Eastern
Cooperative Oncology Group performance status of 0 or 1
(64%) and were International Staging System stage I or II
(57%). A higher percentage of patients in the groups receiving
maintenance therapy had received triplet therapy as induction
therapy (63 and 65% for any maintenance or lenalidomide-
only maintenance therapies, respectively), compared with the
group receiving no maintenance therapy (50%). Table 6
(Online Resource 1) provides the breakdown of types of main-
tenance therapies administered in the group receiving any
maintenance therapy.
Table 2 HRQoL completion and baseline scores
Any maintenance
therapy (n = 244)
Lenalidomide-only
maintenance therapy (n = 169)
No maintenance
therapy (n = 137)
Median (range) duration of maintenance (months) 23.5 (0.6–69.6) 24.9 (0.6–69.6) NA
EQ-5D completion rate, n/N (%)a
Study baseline 241/244 (98.8) 167/169 (98.8) 136/137 (99.3)
Quarter 1 133/243 (54.3) 94/168 (56.0) 107/137 (78.1)
Quarter 2 156/223 (70.0) 110/154 (71.4) 99/123 (80.5)
Quarter 8b 75/116 (64.7) 56/83 (67.5) 48/63 (76.2)
Mean (SD) analysis baseline HRQoL score
FACT-MM total score 118.0 (23.5) 118.9 (23.3) 118.5 (24.1)
FACT-MM trial outcomes index 75.8 (18.5) 76.4 (18.6) 76.0 (19.3)
FACT-MM MM subscale 38.2 (9.7) 38.3 (9.9) 38.9 (9.4)
EQ-5D overall index 0.79 (0.14) 0.79 (0.14) 0.79 (0.14)
BPI 4.0 (2.4) 4.0 (2.4) 3.9 (2.5)
ASCT autologous stem cell transplant, BPI Brief Pain Inventory, EQ-5D EuroQol Research Foundation EQ-5D questionnaire, FACT-MM Functional
Assessment of Cancer Therapy-Multiple Myeloma, HRQoL health-related quality of life, NA not applicable, SD standard deviation
a Completion rates for all instruments were similar because measures were administered at the same times
bData through quarter 8 was selected to correspond with the ~ 24-month median duration of maintenance therapy
Any maintenance
(n = 244)
No maintenance
(n = 137)
Protocol eligible
(N = 1493)
Treated
(n = 1450)
Not treated
(n = 43)
No ASCT
(n = 912)
Ineligible (n = 98)
 •Allogenic SCT (n = 4)
 •Unknown SCT (n = 6)
 •Tandem SCT (n = 32)
 •Consolidation before maintenance (n = 11)
 •SCT after first progression (n = 45)
No forms in analytic period (n = 69)
Received ASCT
(n = 548)
LEN-Only maintenance
(n = 169)
Fig. 2 Patient disposition.
Autologous stem cell transplant
(ASCT), lenalidomide (LEN).
aPatients were excluded if they
received allogenic or unknown
stem cell transplant (SCT),
tandem SCT, or consolidation
before maintenance in course 1 or
if they received SCT after first
progression
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HRQoL questionnaires completion rates and baseline
scores
Median follow-up time was 39.3 months (range, 0.0–
87.1 months) at the time of data cutoff (July 2016). The median
duration of maintenance treatment was 23.5 months (range,
0.6–69.6 months) in the group receiving any maintenance ther-
apy and 24.9 months (range, 0.6–69.6 months) in the group
receiving lenalidomide-only maintenance therapy (Table 2).
During the analysis period, the completion rate for the FACT-
MM was higher in the non-maintenance group (odds ratio 1.4;
Table 2); results were similar for the other tools. Increased com-
pletion rates may be due to closer follow-up and thus more
frequent clinic visits in patients not receiving maintenance.
However, among high completers (> 75% of forms) and low
completers (< 25% of expected forms), there were no differ-
ences in baseline characteristics (e.g. age, race, sex, disease
stage, performance status, renal insufficiency); slight differ-
ences in completion were seen between academic and commu-
nity settings (data not shown). Mean analysis baseline scores
for the EQ-5D, FACT-MM (total, TOI, and MM subscale), and
BPI were similar across groups (Table 2).
Pre-ASCT 100 d
0
160
140
120
100
80
60
40
20
0
5
10
15
20
25
1 2 3 4
Quarters from 100 days post-transplant
R
aw
 d
iff
er
en
ce
s
5 6 7 8
Statistical analysis results:
Estimated difference Len-Only maintenance vs None: 0.7026, P value: 0.7171
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Statistical analysis results:
Estimated difference Any maintenance vs None: -0.9514, P value: 0.5971
Any maintenance
No maintenance
P < 0.001 P = 0.001 P < 0.001
Pre-ASCT DPtAenilesabydutS
Any maintenanceb
(n = 244)
LEN-Only maintenanceb
(n = 169)
No maintenance
(n = 137)
During follow-upa
a
b
c
Fig. 3 FACT-MM total score
change from pre-ASCT baseline
(adjusted) values. FACT-MM
total score scale is 0 to 164. aAny
maintenance therapy (solid line)
versus no maintenance therapy
(dashed line). b Lenalidomide-
only maintenance therapy (solid
line) versus no maintenance
therapy (dashed line). c HRQoL
at baseline, pre-ASCT, during
follow-up, and at PD. Autologous
stem cell transplant (ASCT),
Functional Assessment of Cancer
Therapy-Multiple Myeloma
(FACT-MM), health-related
quality of life (HRQoL),
lenalidomide (LEN), least-
squares (LS), progressive disease
(PD)..aLS mean during the
analysis period, b66 patients had
PD
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HRQoL analyses
No statistically significant differences in change from pre-
ASCT baseline values were observed between the groups re-
ceiving any maintenance therapy and lenalidomide-only
maintenance therapy versus the group receiving no mainte-
nance therapy for the FACT-MM total score (Fig. 3a, b),
TOI score (Fig. 4a, b), and myeloma subscale score (Fig. 5a,
b; Table 7 [Online Resource 1]). Across the treatment groups,
FACT-MM total score, TOI score, and MM subscale score
increased significantly from pre-ASCT to the follow-up
period (P < 0.001 for all groups) and decreased significantly
at progression (P < 0.01, all groups; Figs. 3c, 4c, and 5c).
There were no statistically significant differences in change
in EQ-5D overall index scores over time between the group
receiving no maintenance therapy and the groups receiving
any maintenance (P = 0.98) or lenalidomide-only mainte-
nance therapy (P = 0.46; Fig. 6a, b; Table 7 [Online
Resource 1]). Across groups, EQ-5D overall index score in-
creased significantly from pre-ASCT to the follow-up period
(P < 0.001 for all groups) and decreased at progression (Fig.
6c). The decrease at progression reached statistical
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Statistical analysis results:
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Statistical analysis results:
Estimated difference Any maintenance vs None: -0.8187, P value: 0.5700
Any maintenance
No maintenance
P < 0.001 P < 0.001 P = 0.001 P < 0.001
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Fig. 4 FACT-MM TOI change
from pre-ASCT baseline values
(adjusted). FACT-MM TOI scale
is 0 to 112. a Any maintenance
therapy (solid line) versus no
maintenance therapy (dashed
line). b Lenalidomide-only
maintenance therapy (solid line)
versus no maintenance therapy
(dashed line). c HRQoL at
baseline, pre-ASCT, during
follow-up, and at PD P values are
paired t test comparisons between
periods within treatment group.
The TOI is the sum of the
physical well-being, functional
well-being, and Badditional
concerns^ subscores. Autologous
stem cell transplant (ASCT),
Functional Assessment of Cancer
Therapy-Multiple Myeloma
(FACT-MM), health-related
quality of life (HRQoL),
lenalidomide (LEN), least-
squares (LS), progressive disease
(PD), trial outcome index (TOI).
aLS mean during the analysis
period, b66 patients had PD, c45
patients had PD, d44 patients had
PD
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significance in the groups receiving lenalidomide-only main-
tenance therapy (P = 0.001; Fig. 6c) and no maintenance ther-
apy (P = 0.049).
Change in BPI scores from baseline also did not differ
significantly between the groups for those receiving any main-
tenance therapy versus no maintenance therapy (P = 0.81) and
those receiving lenalidomide-only maintenance therapy ver-
sus no maintenance therapy (P = 0.42; Fig. 7a and b; Table 7
[Online Resource 1]). BPI decreased significantly from pre-
ASCT (analytic baseline) to follow-up for the groups receiv-
ing any maintenance therapy and lenalidomide-only
maintenance therapy and significantly increased at progres-
sion for all groups (P < 0.001; Fig. 7c [Online Resource 1]).
Discussion
The findings from this analysis of PRO data from the Connect
MM patient registry showed no deterioration in HRQoL, de-
spite continued active therapy in the maintenance therapy
groups. Patient-reported HRQoL using the FACT-MM, EQ-
5D Index, and BPI improved after transplant in all three
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Statistical analysis results:
Estimated difference Any maintenance vs None: -0.0469, P value: 0.9486
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Statistical analysis results:
Estimated difference Len-Only maintenance vs None: 0.7109, P value: 0.3619
Len-Only maintenance
No maintenance
P < 0.001 P < 0.001 P = 0.001 P < .001 P < .001
Pre-ASCTStudy baseline At PD
Any maintenanceb
(n = 244)
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(n = 169)
No maintenanced
(n = 137)
During follow-upa
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c
Fig. 5 FACT-MM MM subscale
change from pre-ASCT baseline
values (adjusted). FACT-MM
MM subscale is 0 to 56. a Any
maintenance therapy (solid line)
versus no maintenance therapy
(dashed line). b lenalidomide-
only maintenance therapy (solid
line) versus no maintenance
therapy (dashed line). c HRQoL
at baseline, pre-ASCT, during
follow-up, and at PD. P values are
paired t.test comparisons between
periods within treatment group.
Autologous stem cell transplant
(ASCT), Functional Assessment
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analysis period. b66 patients had
PD. c45 patients had PD. d44
patients had PD
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groups and numerically deteriorated on progression.
Deterioration of HRQoL scores was significant when assessed
with the FACT-MM total score and specific subscales (TOI
and MM-Scale). Interestingly, HRQoL was measured before
patients being informed of disease progression; thus, HRQoL
deterioration was observed independently. A trend towards
greater improvement in HRQoL was observed in the groups
receiving any maintenance therapy and lenalidomide-only
maintenance therapy, as compared with the group receiving
no maintenance therapy. Results were consistent across all
HRQoL measures.
Given that prolonged therapy is associated with improved
prognosis, understanding therapy-related decrements to
HRQoL has become increasingly important. Key consider-
ations when deciding whether maintenance therapy should
be recommended could include an individual’s risk factors
and depth of response, weighed by the potential for toxicities
that accompany continued treatment and potential HRQoL
impairments.
Results of phase 3 randomized trials have shown consis-
tently that post-ASCT lenalidomide maintenance therapy sig-
nificantly extends the duration of remission as compared with
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no maintenance therapy [5, 8, 10, 29]. Recently, a meta-
analysis of three phase 3 trials showed a significant OS benefit
for lenalidomide maintenance therapy versus no maintenance
therapy [17]. With significant improvements in PFS, results of
the Myeloma XI study (N = 1550) support use of maintenance
lenalidomide as standard of care regardless of patient age [22].
Although rates of hematologic AEs and discontinuation be-
cause of AEs reported have been higher for patients receiving
lenalidomide maintenance therapy compared with placebo,
the general toxicity profile is manageable [8, 10]. Second pri-
mary malignancies were higher for patients receiving
lenalidomide maintenance therapy; however, when compared
with the meaningful survival improvement, the benefit–risk
profile remained positive [17]. However, PROs were not col-
lected in these studies; therefore, HRQoL outcomes were not
adequately assessed.
Connect MM is the first and largest prospective registry of
patients with NDMM in the USA. The collection of longitudi-
nal data on clinical practice and treatment outcomes in both
clinical and nonclinical trial settings among patients predomi-
nantly treated in community-based practices provides a rich
understanding of real-world clinical practices. Because of the
large volume of data, findings from this study reflect real-
world clinical practice; therefore, the generalizability of find-
ings and potential to inform patient care represent major
strengths. Registry study analyses can be confounded by lim-
itations in data entry or data reporting and by the observational,
nonrandomized nature of the study. Since these patients were
treated at their physicians’ discretion, using HRQoL assess-
ments collected immediately prior to the initiation of mainte-
nance therapy could increase the variability of HRQoL scores
among patients; therefore, analytical baseline for HRQoL as-
sessments was immediately prior to ASCT. Post-baseline as-
sessments began at 100 days post-ASCT and were conducted
quarterly. However, our post-baseline completion rates for
HRQoL instruments (ranging from 56 to 82% for EQ-5D
through Quarter 8) were similar to those reported in a phase
3 clinical trial (MM-015) of lenalidomide maintenance therapy
versus no maintenance therapy after lenalidomide-melphalan-
prednisone treatment in older patients (aged ≥ 65 years) with
newly diagnosed MM [30], as well as in a phase 3 trial (MM-
020) of lenalidomide-dexamethasone versus melphalan-
prednisone-thalidomide in newly diagnosed MM (EQ-5D
65–92% through month 18; data on file). Another limitation
of this study is that the impact of AEs on PROs was not
assessed. Finally, there is a drop-off in patients with clinical
and HRQoL data during the follow-up period (as is expected
for a registry study); however, patient demographics and dis-
ease characteristics were similar at baseline between those
completing and not completing HRQoL assessments.
In conclusion, these results show that post-ASCT mainte-
nance therapy, including lenalidomide-only maintenance ther-
apy, did not negatively affect HRQoL in patients in the
Connect MM Registry. Patients had generally similar scores
on measures assessing overall HRQoL, myeloma-specific con-
cerns, pain severity, and health utilities, regardless of mainte-
nance or no maintenance therapy after ASCT. These findings
suggest that continued, active, post-ASCT maintenance thera-
py does not decrease HRQoL while improving clinical out-
comes, thus supporting a favorable benefit–risk profile.
Confirmation of these outcomes with a longer follow-up and
in the Connect MM registry Cohort 2 is warranted.
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